Squarepoint
RVNC

Squarepoint’s Revance Therapeutics, Inc. RVNC Stock Holding History

Squarepoint’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,600
Closed -$38.3K – 5626
2024
Q4 		$38.3K Buy
+12,600
New +$54.9K ﹤0.01% 4883

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Squarepoint's RVNC Position: Q1 2025 in Review

Squarepoint sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 3,164,943 shares — an estimated $9.62M sold.

Squarepoint first reported a position in RVNC in Q4 2017 and held it in 20 quarters. The position peaked at $12M in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Squarepoint reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Squarepoint sold 3,164,943 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $9.62M.
  • Squarepoint first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 20 quarters.
  • Squarepoint's Revance Therapeutics, Inc. position peaked at $12M in Q3 2024.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Squarepoint's 13F filing for Q1 2025, filed 15 May 2025.